WuXi Biologics Recognized Among Industry Leaders for Sustainable Biopharma Practices
核心洞察
WuXi Biologics was featured in BioPharma APAC's "Top 26 - Companies Leading Sustainable Biopharma Practices in 2026" for its Green CRDMO solution and sustainability performance.
The Company's Green CRDMO integrates sustainability across research, development, manufacturing, and operations, with SBTi-validated near-term, long-term, and net-zero targets including net-zero emissions by 2050.
Key technologies such as WuXiUI™ and single-use technology reduce lifecycle environmental impacts by up to 60% and product carbon footprint per gram of protein by up to 80%.
WuXi Biologics has been recognized among the industry's leading sustainable biopharma companies, earning a place in BioPharma APAC's "Top 26 - Companies Leading Sustainable Biopharma Practices in 2026." The list highlights leading sustainability practices across pharmaceutical companies, biotechnology firms, and CRDMOs in Europe, North America, and Asia Pacific, with a focus on Science Based Targets initiative (SBTi) commitments, value-chain decarbonization, green manufacturing, and sustainable operations.
The recognition places WuXi Biologics alongside global pharmaceutical leaders such as MSD (Merck & Co.) (搜索), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda (搜索), GSK, and Bayer (搜索), collectively illustrating the diverse pathways through which players across the industry value chain are advancing the green transition. WuXi Biologics was featured for its outstanding sustainability practices, reflecting international industry recognition of the Company's empowering contributions through green CRDMO.
Green CRDMO: Sustainability as an Integrated Capability
At WuXi Biologics, sustainability has evolved from a corporate social responsibility requirement into an important driver of industry advancement and corporate competitiveness. The Company's Green CRDMO solution turns sustainability into an integrated capability that is practical, measurable, and empowering, connecting sustainability progress with productivity, operational resilience, and long-term competitiveness to create tangible and sustainable value for global clients.
"Green CRDMO solution is therefore not an add-on to traditional services, but a bridge that translates governance practices into business value," the Company stated, noting that the approach helps clients enhance corporate governance, reduce operating costs, capture green-financing opportunities, establish product-level carbon transparency, strengthen competitiveness in government procurement that emphasizes ESG performance, and improve overall supply-chain resilience.
Green Research and Development
In Green Research, WuXi Biologics operates under the principle "For Patients. For Planet." The Company leverages its integrated end-to-end CRDMO platform and innovative technologies to shorten the journey from molecule to patient. Discovery platforms such as WuXiBody™ accelerate the development of antibodies and complex molecules, improve developability and stability, and enable innovative therapies to reach patients faster, at greater scale, and with higher quality. By simplifying bispecific antibody development and shortening R&D timelines by 6–18 months, WuXiBody™ improves R&D efficiency while reducing the natural resources and energy required to maintain research environments.
In Green Development, WuXi Biologics uses advanced platforms including WuXia™, WuXiUP™, and WuXiUI™ to improve productivity, reduce resource use, and provide more efficient and flexible process pathways for innovative biologics. The WuXia™ TrueSite cell line development platform achieves monoclonal antibody titers of 8–12 g/L, supporting high-yield commercial manufacturing requirements, and shortens the timeline to approximately six months from DNA to IND filing readiness. The WuXiUI™ ultra-intensified fed-batch platform boosts productivity by 3 to 8 times and reduces lifecycle environmental impacts by up to 60% compared with traditional fed-batch processes.
Green Manufacturing and Operations
In Green Manufacturing, WuXi Biologics leverages single-use technology (SUT) and process innovation to scale green manufacturing. Compared with traditional stainless-steel processes, SUT can save up to 70% of water, reduce resource use by approximately 33%, and lower negative climate-change impacts by approximately 40%. End-of-life treatment accounts for only 1%–3% of its lifecycle environmental impact. Combining WuXiUI™ with SUT can reduce the product carbon footprint per gram of protein by up to 80%, providing clients with manufacturing solutions that deliver both environmental and operational benefits.
The Company also uses lifecycle assessment (LCA) modeling and calculation capabilities to support cradle-to-gate product carbon-footprint measurements and enable product-level carbon transparency. In Green Operations, WuXi Biologics embeds sustainability across its global operations, using lean management and digital tools to improve resource and energy efficiency. Its Green CRDMO solution was selected as a United Nations Global Compact "20 Cases for 20 Years" corporate sustainability case, and the WuXi Biologics Green CRDMO White Paper outlines 242 energy-saving cases covering 12 major energy systems and five key energy-saving scenarios across 25 categories of energy-saving technologies.
Climate Commitments and Recognition
Climate action remains a central pillar of the Company's Green CRDMO strategy. WuXi Biologics has obtained SBTi validation for its near-term, long-term, and net-zero targets, and has committed to achieving net-zero emissions across its value chain by 2050. BioPharma APAC specifically highlighted WuXi Biologics' SBTi-approved targets and commitment to sustainable transformation within the biopharmaceutical industry.
WuXi Biologics has continued to receive international recognition for its sustainability performance, including the highest MSCI AAA ESG rating; the EcoVadis Platinum Medal, placing the Company in the global top 1%; inclusion in the Dow Jones Best-in-Class World Index and Dow Jones Best-in-Class Emerging Markets Index; CDP "A List" recognition for Climate Change, Water Security, and Supplier Engagement Assessment; the highest "Negligible Risk" rating from Morningstar Sustainalytics; inclusion in the FTSE4Good Index Series; ISS ESG Prime status; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio. The Company employs over 13,000 people across China, the United States, Ireland, Germany, and Singapore.